Obesity and nonalcoholic fatty liver disease: metabolic risks and their correction


Nonalcoholic fatty liver disease (NAFLD) – a common chronic disease of the liver, the main feature of which is the accumulation of fat in hepatocytes, is not related to alcohol abuse. NAFLD is associated with obesity, especially abdominal, metabolic syndrome and various metabolic markers of risk for cardiovascular disease and type 2 diabetes, which affects the incidence, prognosis and life expectancy of patients with obesity. This lecture describes the main causes of the disease, its pathogenesis, clinical presentation, diagnosis and treatment.

About the authors

Kseniya Andreevna Komshilova

Endocrinology Research Centre

Author for correspondence.
Email: kom-ksusha@rambler.ru

Russian Federation researcher at the the  Therapy Department with a group of obesity

Ekaterina Anatol'evna Troshina

Endocrinology Research Centre

Email: troshina@inbox.ru

Russian Federation MD, Ph.D. Professor, Head of the  Therapy Department with a group of obesity


  1. Lazo M, Clark JM, editors. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Seminars in liver disease; 2008; 28(4): Р. 339-50.
  2. Musso G, Gambino R, Cassader M. Non‐alcoholic fatty liver disease from pathogenesis to management: an update. Obesity Reviews. 2010;11(6):430-45.
  3. Буеверов А.О. Хронические заболевания печени. Краткое руководство для практикующих врачей. – М.: "МИА"; 2013. [Bueverov AO. Khronicheskie zabolevaniya pecheni. Kratkoe rukovodstvo dlya praktikuyushchikh vrachey. Moscow: "MIA"; 2013. (In Russ).]
  4. Dowman JK, Tomlinson J, Newsome P. Pathogenesis of non-alcoholic fatty liver disease. Qjm. 2010;103(2):71-83.
  5. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New England Journal of Medicine. 2010;363(14):1341-50.
  6. Lau E, Carvalho D, Freitas P. Gut Microbiota: Association with NAFLD and Metabolic Disturbances. BioMed Research International. 2015. doi: 10.1155/2015/979515
  7. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-23. doi: 10.1002/hep.25762
  8. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21. doi: 10.1002/hep.20701
  9. Adams L, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgraduate medical journal. 2006;82(967):315-22. doi: 10.1136/pgmj.2005.042200
  10. Marchesini G, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in nonalcoholic steatohepatitis. The Lancet. 2001;358(9285):893-4. doi: 10.1016/S0140-6736(01)06042-1
  11. Nair S, Diehl A, Wiseman M, Farr G, Perrillo R. Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial. Alimentary pharmacology & therapeutics. 2004;20(1):23-8.
  12. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology & Therapeutics. 2011;34(3):274-85. PMID:21623852 doi: 10.1111/j.1365-2036.2011.04724.x



Abstract - 1508

PDF (Russian) - 1571



Copyright (c) 2015 Комшилова К.А., Трошина Е.А.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies